Evidence map›Paper›PMID 32435126›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2020

A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery.

Qiangqiang Tao, Fang Fang, Jiaming Li, Yong Wang, Can Zhao, Jingtai Liang, Xiaodong Ma, Hao Wang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qiangqiang Tao1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Fang Fang1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Jiaming Li1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Yong Wang1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Can Zhao1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Jingtai Liang1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Xiaodong Ma1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012 China.
Hao Wang3Department of Clinical Laboratory, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001 China.
Anhui University of Traditional Chinese Medicine · CNUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mTOR/MEK bifunctional inhibitors have the potential to surmount the drug resistance aroused from cross talk between PI3K/Akt/mTOR (PAM) and Ras/MEK/ERK pathways. Herein, we report the discovery of a conjugated dual-targeted molecule, compound

Indexed as

Allosteric MEK inhibitorCross talkDrug resistancemTOR kinase inhibitormTOR/MEK bifunctional inhibitor

Identifiers

PMID32435126
PMCPMC7223898
OpenAlexW2999937226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.